Regenxbio vs Xencor
Regenxbio reported revenue of $170 million in fiscal 2025, 1.4 times Xencor's $126 million in fiscal 2025. Regenxbio's revenue grew 104.5% in its latest year, and Xencor's grew 13.7%. Regenxbio had an operating margin of -94.6%, against -141.3% at Xencor. Free cash flow was −$126 million at Regenxbio and −$138 million at Xencor.
Side by side
| Regenxbio | Xencor | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $170M | $126M |
| Revenue growth | 104.5% | 13.7% |
| Revenue growth a year, last 5 years | 2.0% | 0.5% |
| Gross margin | — | — |
| Operating margin | −94.6% | −141.3% |
| Net margin | −113.8% | −73.2% |
| Free cash flow | −$126M | −$138M |
| Free cash flow margin | −74.2% | −110.1% |
| Return on capital | — | −19.9% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 4.2% | 14.1% |
| Last close | $7.64 | $37.09 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $7.4 million |
| Piotroski F-score | — | 3 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
RegenxbioXencor
Operating margin
Percent of revenue
RegenxbioXencor
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
RegenxbioXencor